Portfolio Case
    • Founder and Chairman of Efung Capital

    • Tsinghua PBCSF MAB


    • DBA Candidate of Paris School of Business (PSB)

    • Honorary Chairman of HKBMIA

    • Sino-PhIRDA Investment Committee Sponsor

    • Bayhelix Group Member


    Dedicated to healthcare industry investment for 20 years, Mr. Zhu He has played a leading role in investing serval promising pharmaceutical projects, and fostered the development of healthcare industry in China. Thus Mr. Zhu was nominated for “China Finance Person of The Year 2019”, “Top 10 Healthcare Investor 2019”and “2020 Best Investor in Healthcare Industry”.


    Mr. Zhu has displayed his excellent expertise in healthcare investment, his classical investment portfolios include: Mindray, Chipscreen Bioscience, Frontier Biotech, Ascentage Pharma, Lifotronic Technology, Harbour BioMed, OBiO Technology, Asieris Pharma, Biostar Technologies, 3D Medicines, Centrexion and Apexigen et al.

    • Former president of China Merchants Bank

    • Executive director of China Financial Society

    • Honorary doctor, University of Southern California

    • Outstanding Chinese Entrepreneurs

  • ·Bachelor of Economics at University of California San Diego.

    Former project manager of Guoxin Securities Asset Management Headquarters; responsible for the bank-certificate

    cooperation related projects including but not limited to entrusted loans, direct fund investment, trust income rights and other related businesses with a total scale of 30 billion RMB.

  • ·Xi 'an jiaotong university bachelor of business administration, cheung kong graduate school of business EMBA.
    ·Former Executive VP of a yacht club. Former CEO of Shenzhen Voyage Century Technology CO., LTD.
    ·As marketing directors, arranged for the openings of 3 top-class hotels in Shenzhen.

  • ·Co-founder of Huawei Technologies Co., Ltd.
    ·Over 40 years of experience in financial management; Over 20 years of experience in the communication industry.
    ·Served as the vice president of accounting, marketing, finance and economics in Huawei.

    Has participated in the Huawei's equity management,restructure, enterprise operations and many other projects.

    Joined Efung since 2012 as a managing partner. Responsible for risk management.

  • ·

    Doctor of Medicine at Beijing Medical University and Ph.D., at Japan Autonomous Medical University.


    Director of Chinese Disease Control and Prevention Center from 2004 to 2017.


    Distinguished Professor of Tsinghua University;Vice President of the Chinese Preventive Medicine Association, and Executive Director of the Chinese Medical Association. Director of the Institute of Liver Diseases of Beijing Medical University; Vice President of Beijing Medical University; 

    Deputy Director of the Department of Medicine at Peking University, and Deputy Director of Ministry of Science and Technology of China Biotechnology Development Center.


    Won the first prize of National Science and Technology Progress Award, the first prize of Science and Technology Progress of the Ministry of Health, the National Science and Technology Progress Special Award, and the National Outstanding Youth Science Fund.

  • Pharmacy Doctor, Fudan University,

    Research and investment in the field of anti-tumor drugs,

    Experiences in consulting and healthcare investment,

    Overseas mergers and acquisitions & innovative drug investment

  • Postdoctoral from Stanford University, former head of competitive intelligence and strategy in Novartis, Over 20 years of pharmaceutical industry research experience

  • Doctor of chemistry, University of Manchester,  Research and investment in innovative drugs & surgical robots, Several cases in innovative drugs and medical devices investment

  • M.D., MSc of health economics from Johns Hopkins University,

    Investment in innovative drugs from the perspective of clinical needs, Work experiences in WHO headquarters and global leading healthcare information, R&D service enterprise

  • Postdoctoral from Harvard Univ. Applied 4 Chinese patents and published 16 SCI papers,

    Specializes in drug discovery,  nuclear medicine and molecular imaging.

  • Doctor from Cambridge University and Jilin University,

    Specialized in research and investment of innovative drugs

    Member of Guangdong pharmacological society and Anti-tumor Drug Professional Committee

  • Organic chemistry Ph.D. from Cambridge University

    Shenzhen Peacock Talent

    Over 10 years of drug research, specializes total synthesis of natural products and drugs

  • MSc of Biology, Sun Yat-Sen University, Focuses on gene, cell therapy, high-end medical device research and investment, many years of VC/PE investment experience, with > 10 successful investment cases, including 3 IPO projects

  • MSc from Sun Yat-Sen University & Kansai University, with molecular biology and financial background, work experience in top biomedical investment firm

  • BSc from Shanghai Jiaotong University with law background,
    former invest manager in ZhongCai Financial Holding & ZCT

  • Ph.D. from Oxford University,

    CFA candidate, work experience in biomedical research, doctoral start-up program won first prize in UK

Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services